Screening devices and methods for obstructive sleep apnea therapy

Information

  • Patent Grant
  • 9555247
  • Patent Number
    9,555,247
  • Date Filed
    Monday, July 20, 2015
    9 years ago
  • Date Issued
    Tuesday, January 31, 2017
    7 years ago
Abstract
Devices and methods for treating obstructive sleep apnea by first performing an assessment of the patient that involves observing the patient's upper airway during a tongue protrusion maneuver. The assessment may, for example, be done using endoscopy to observe the upper airway while the patient is awake in the supine position. An adequate response of the upper airway during the tongue protrusion maneuver is indicative of likely therapeutic success with hypoglossal nerve stimulation, and may be used for making clinical decisions. The principles of the present invention may be applied to other therapeutic interventions for OSA involving the upper airway.
Description
FIELD OF THE INVENTION

The inventions described herein relate to devices and methods for assessing and treating the upper airway. More particularly, the inventions described herein relate to devices and methods for assessing and treating the upper airway in patients with obstructive sleep apnea.


BACKGROUND OF THE INVENTION

Hypoglossal nerve stimulation has been proposed for the treatment of obstructive sleep apnea. An example of an implantable hypoglossal nerve stimulation system is described in U.S. Pat. No. 7,809,442 to Bolea et al. Published data suggest that response to hypoglossal nerve stimulation varies across subjects. Before undergoing a surgical procedure to implant a hypoglossal nerve stimulation system, it would be desirable to understand the likelihood of therapeutic success, and make clinical judgments accordingly.


SUMMARY OF THE INVENTION

To address this and other unmet needs, the present invention offers, in one example embodiment, a method for treating obstructive sleep apnea by first performing an assessment of the patient that involves observing the patient's upper airway during a tongue protrusion maneuver. The assessment may, for example, be done using endoscopy to observe the upper airway while the patient is awake in the supine position. The tongue protrusion maneuver may, for example, involve the patient volitionally protruding the tongue to its maximal extent with the mouth open or the lips loosely touching the tongue. The tongue protrusion maneuver mimics the effect of genioglossus activation by hypoglossal nerve stimulation (HGNS). Thus, an adequate increase in airway size during the tongue protrusion maneuver would be indicative of likely therapeutic success with HGNS. If the assessment shows an adequate increase in airway size during the maneuver, a HGNS device may be implanted in the patient with a higher confidence in a successful outcome. The principles of the present invention may be applied to other therapeutic interventions for OSA involving the upper airway.





BRIEF DESCRIPTION OF THE DRAWINGS

It is to be understood that both the foregoing summary and the following detailed description are provided by way of example, not limitation. Together with the following detailed description, the drawings illustrate example embodiments and serve to explain certain principles of the invention. In the drawings,



FIG. 1 is a schematic illustration of a hypoglossal nerve stimulation system;



FIGS. 2A and 2B are schematic illustrations showing simplified structures of the upper airway in a lateral dissection with the palate and mandible shown in medial sagittal section;



FIG. 3A is a schematic illustration showing an endoscope inserted into the airway



FIGS. 3B and 3C are views of the upper airway from the endoscope shown in FIG. 3A while the tongue is in a resting awake state (FIG. 3B) and during a tongue protrusion maneuver (FIG. 3C);



FIG. 3D is a schematic illustration of a modified endoscope;



FIG. 4 is a schematic illustration showing the structures of the upper airway in a lateral dissection with the palate and mandible shown in medial sagittal section;



FIG. 5 is a schematic illustration showing the structures of the upper airway from the oral cavity;



FIG. 6 is a schematic illustration showing isolated structures of the upper airway in a transverse section;



FIG. 7 is a schematic illustration showing structures of the upper airway in a posterior dissection of the interior pharynx;



FIG. 8 is a schematic illustration showing structures of the upper airway in a posterior dissection of the exterior pharynx;





DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.



FIG. 1 schematically illustrates a hypoglossal nerve stimulation (HGNS) system 100 comprising internal components 200 and external components 300. The HGNS system 100 is intended to treat obstructive sleep apnea (OSA) by increasing neuromuscular activity of the genioglossus muscle via stimulation of the hypoglossal nerve (HGN) synchronous with inspiration to mitigate upper airway collapse during sleep. Stimulation is generated by an implantable neurostimulator (INS) 210, synchronized with inspiration as measured by the respiration sensing lead (RSL) 220 using bio-impedance, and delivered to the hypoglossal nerve by a stimulation lead (STL) 230. A programmer system 310 and a therapy controller 320 are wirelessly linked to the INS 210. The programmer system 310 includes a computer 330, a programmer interface 340, and a programmer head 350. The programmer system 310 is used by the physician to control and program the INS 210 during surgery and therapy titration, and the therapy controller 320 is used by the patient to control limited aspects of therapy delivery (e.g., start, stop, and pause).


The implanted components 200 of the HGNS system 100 include the INS 210, STL 230, and RSL 320. The INS is designed to accommodate one STL 230 and one RSL 220. One STL 230 may be used for unilateral implantation and unilateral hypoglossal nerve stimulation. Similarly, one RSL 220 may be used for respiration detection, and may be bifurcated as shown.


The implanted components 200 may be surgically implanted with the patient under general anesthesia. The INS 210 may be implanted in a subcutaneous pocket inferior to the clavicle over the pectoralis fascia. The distal end of the STL 230 (cuff 235) may be implanted on the hypoglossal nerve or a branch of the hypoglossal nerve in the submandibular region, and the proximal end of the STL 230 may be tunneled under the skin to the INS 210. The RSL 220 may be tunneled under the skin from the INS 210 to the rib cage and placed on both lateral sides of the costal margin. The INS 210 detects respiration via the RSL 220 using bio-impedance and stimulates the hypoglossal nerve via the STL 230 synchronous with inspiration.


Further aspects of the HGNS system 100 may be found in U.S. Provisional Patent Application No. 61/437,573, filed Jan. 28, 2011, entitled OBSTRUCTIVE SLEEP APNEA TREATMENT DEVICES, SYSTEMS AND METHODS, the entire disclosure of which is incorporated herein by reference.


Patients with obstructive sleep apnea have repeated episodes of complete (apnea) or partial (hypopnea) upper airway collapse during sleep. The upper airway is generally defined by four walls: the posterior pharyngeal wall, the right and left lateral pharyngeal walls, and anteriorly, the soft palate and the tongue. The posterior pharyngeal wall is relatively fixed to the spinal column. Thus, collapse of the upper airway generally involves, depending on the level and mode of collapse, the tongue, the soft palate and/or the lateral walls. In rare cases, collapse may involve the nasopharynx and/or hypopharynx. As seen in FIG. 2A, the tongue and the soft palate have been displaced posteriorly, thus occluding the airway at the level of the tongue (retro-glossal collapse) and at the level of the soft palate (retro-palatal collapse). As seen in FIG. 2B, activation of the genioglossus muscle, for example by HGNS, causes anterior displacement of the tongue, thus opening the retro-glossal airway space. Activation of the genioglossus muscle can also cause anterior displacement of the soft palate, thus opening the retro-palatal airway space. Although not visible in this view, activation of the genioglossus muscle can further cause lateral displacement of the lateral pharyngeal walls, thus further opening the upper airway. In this manner, activation of the genioglossus muscle, for example by HGNS, can mitigate upper airway collapse in OSA subjects.


Although the effect of genioglossus activation on the tongue to open the retro-glossal airway is predictable given the mechanism of action, the effect of genioglossus activation on the soft palate and lateral walls has been heretofore poorly understood and variable across subjects. Nevertheless, in the majority of OSA patients, the soft palate and the lateral walls can contribute to upper airway collapse, alone or in combination with the tongue. Thus, observing these effects can be important to predicting the success of HGNS therapy. This is particularly true if the soft palate and/or lateral walls are known to contribute to airway collapse for a given OSA patient.


The present invention offers a method to mimic genioglossus activation to observe and assess the effects thereof on structures of the upper airway. The method generally involves causing the tongue to protrude while observing the response of the upper airway using an imaging technique. In general, the desired response is an increase in airway size. An adequate increase in airway size during the tongue protrusion maneuver is indicative of likely therapeutic success with HGNS. If an adequate increase in airway size is observed during the maneuver, a HGNS device may be implanted in the patient with a higher confidence of a successful outcome.


With reference to FIG. 3A, a naso-endoscope 400 may be used to visually observe the upper airway while the patient is awake in the supine position. Alternatively, the observation may be made while the patient is in a seated or semi-recumbent position. A conventional naso-endoscope 400 including a fiber optic shaft 410 and a hand piece 420 may be used. Hand piece 420 may include a light source and a viewing window, and/or facilitate connection to ancillary imaging equipment (e.g., light source, camera, monitor, recorder, etc.). The patient may be asked to volitionally protrude his/her tongue straight and to its maximal extent with the mouth open and the lips loosely touching the tongue. Alternatively, the tongue protrusion may be performed sub-maximally, which may limit muscle contraction to the genioglossus without recruiting other musculature. Also alternatively, the tongue protrusion may be performed by asking the patient to point the tip of the tongue to one side or the other, which may more closely mimic unilateral hypoglossal nerve stimulation. The distal end of the endoscope may be positioned superior to the soft palate and substantially parallel with the posterior pharyngeal wall to visualize the retro-palatal space. The distal end of the endoscope may be positioned inferior to the soft palate, superior to the tongue base and substantially parallel with the posterior pharyngeal wall to visualize the retro-glossal space. An example of the view of the retro-palatal upper airway space with the tongue in a relaxed (nominal) position is shown in FIG. 3B, and the same view with the tongue protruded is shown in FIG. 3C. As can be seen by comparing the views in FIGS. 3B and 3C, tongue protrusion can result in an increase in airway size, including area, circumference, anterior-posterior dimension, and lateral dimension. The increase in airway size at the level of the tongue and palate may be most discernable by an increase in anterior-posterior (AP) dimension between the posterior pharyngeal wall and the posterior side of the tongue base (retro-glossal) and soft palate (retro-palatal), respectively. Since the posterior pharyngeal wall is fixed relative to the spinal column, the increase in AP dimension involves anterior displacement of the tongue and soft palate, respectively. The increase in airway size may also be discernable by an increase in lateral dimension between the right and left lateral pharyngeal walls.


During the tongue protrusion maneuver, observing an adequate increase in size of the retro-glossal airway is predictive of HGNS efficacy in patients with isolated tongue base collapse. However, as mentioned above, the soft palate contributes to upper airway collapse in the majority of OSA patients, thus also observing an increase in size of the retro-palatal airway during the tongue protrusion maneuver is predictive of HGNS efficacy in patients with isolated soft palate collapse and combined tongue plus soft palate collapse.


By way of example, not limitation, the following procedure may be followed to conduct the assessment and tongue protrusion maneuver. With the patient awake in the supine position, a nasal endoscope is inserted into the pharynx via one of the nares to allow visualization of the upper airway. Video and still images may be captured at both the retro-palatal and retro-glossal levels to document the effect of different maneuvers on anatomic structures of the upper airway (tongue, palate, epiglottis, pharyngeal walls, etc.). When imaging the retro-palatal level, the endoscope may be placed such that all four walls (soft palate, posterior wall, and the two lateral walls) of the pharynx are visible before, during and after maneuvers. Similarly, when imaging the retro-glossal level, the endoscope may be placed such that all four walls (tongue base, posterior wall, and the two lateral walls) of the pharynx are visible before, during and after maneuvers. The endoscope may be placed such that it runs generally parallel to the posterior wall and provides a symmetric field of view. This may be achieved by initially placing the distal end of the endoscope near the level of the epiglottis and subsequently pulling back to the desired level. The patient then performs a series of maneuvers, including a tongue protrusion maneuver while breathing through their nose. The tongue protrusion maneuvers involves voluntary maximal straight tongue protrusion with lips loosely touching the tongue, with the mouth completely open, and/or with the teeth clenched closed. Other maneuvers such as a Mueller maneuver (inspiratory efforts against a closed airway) may be performed as well. Each maneuver is held for ≧2 seconds, and performed several times while data (images and measurements) are gathered.


Alternative non-volitional tongue protrusion maneuvers include, for example, manually gripping and pulling the tongue anteriorly (e.g., by the physician), using a tongue retaining device (e.g., as used for the treatment of OSA), both of which are non-invasive. Another alternative is to stretch the palatoglossal arch by pushing the tongue down (depress tongue), by pushing the arch laterally outward, or by pulling the arch anteriorly (all palatoglossal maneuvers) using a tongue depressor or similar device. The palatoglossal maneuver may be used in place of or in combination with the tongue protrusion maneuver, and the entire description herein with respect to the tongue protrusion maneuver is applicable to the palatoglossal maneuver. Other alternative non-volitional tongue protrusion maneuvers include, for example, sub-mental stimulation and intra-muscular stimulation (using fine wire electrodes, for example), both of which are relatively more invasive, but have the benefit of more selectively activating the genioglossus muscle alone to more closely mimic HGNS, as compared to volitional tongue protrusion which may recruit more than the genioglossus muscle.


Although naso-endoscopy is perhaps the most practical imaging technique to employ to assess the response of the upper airway to the tongue protrusion maneuver, other imaging techniques may be used as well. For example, x-ray imaging, fluoroscopy, x-ray computed tomography (CT), and optical coherence tomography (OCT) are suitable alternatives. These alternatives may provide more quantitative measurements by using a reference marker of known dimension in the field of view. Alternatively, improvements may be made to conventional naso-endoscopes to facilitate more quantitative measurements. For example, with reference to FIG. 3D, conventional naso-endoscope 400 includes a fiber optic shaft 410 and a hand piece 420. The distal end of the shaft 410 may include an attached extension 430 having a tip 440. The extension 430 positions the tip 440 into the field of view and may be approximated to the upper airway structure being visualized. The tip 440 may have a known dimension (e.g., diameter of 1 French or 3 mm), such that quantitative measurements of upper airway structures may be made by comparison. Other devices to make quantitative measurements may be employed, such as a laser pointer of know beam diameter projected onto the upper airway structure of interest. As an alternative, a catheter (e.g., nasogastric, nasoesophageal or nasopharyngeal catheter) may be inserted into the nasopharynx such that it resides in the field of view of the endoscope to serve as a quantitative reference of known dimension (e.g., diameter).


As mentioned above, the upper airway assessment during tongue protrusion maneuver may be used as a screening tool wherein the patient is treated with the desired therapy (e.g., HGNS) only if the increase in size of the upper airway meets a predefined criterion. To this end, the response of the upper airway may be measured using a qualitative scale such as a visual analog scale of 0-10, wherein 0 represents a closed airway and 10 represents a completely open or patent airway. The airway size may be scored with the tongue at rest and during the tongue protrusion maneuver. The patient may be treated if the difference between the two scores meets a threshold, if the score during the maneuver meets a threshold, or if both the difference between the scores and the score during the maneuver meet thresholds (e.g., 5 on a scale of 0-10).


Alternatively, the response of the upper airway may be measured using a quantitative scale such as: a pixel count of captured images which may be representative of cross-sectional area; a linear dimension such as anterior-posterior and/or lateral; or a measure of circumference. Here again, the airway size may be measured (e.g., pixel count, AP length, and/or lateral width) with the tongue at rest and during the tongue protrusion maneuver. The patient may be treated if the difference between the two measures meets a threshold, if the measure during the maneuver meets a threshold, or if both the difference in measures and the measure during the maneuver meet thresholds.


In each case, the threshold may be a percentage increase in size (e.g., difference in AP length=50%), an absolute value (e.g., difference of AP length=0.5 cm), or a relative value. The relative value may be with reference to an anatomical landmark such as the width of the superior aspect of the epiglottis (e.g., difference in AP length=50% of epiglottal width).


Other response criteria observed during the tongue protrusion maneuver, in addition to an increase in airway size, may be used as well. For example, movement of the hyoid bone may be observed visually, by palpation or by x-ray. Movement of the hyoid bone in an anterior direction and/or inferior direction during the tongue protrusion maneuver may be predictive of therapeutic success with HGNS.


As mentioned above, although the effect of HGNS and genioglossus activation on the tongue to open the retro-glossal airway is predictable given the mechanism of action, the effect of genioglossus activation on the soft palate and lateral walls has been heretofore poorly understood. The explanation lies in the mechanical linkages between the genioglossus and other pharyngeal structures defining the upper airway. The linkages are primarily muscular, and can be effective without independent activation. Nevertheless, it may be desirable to independently activate any one or a combination of the muscular structures described below by stimulating the muscle directly or by stimulating the corresponding motor nerve innervating the muscle.


With reference to FIG. 4, the mechanical linkages may be explained in more detail. By way of context, the hypoglossal nerve (cranial nerve XII) innervates the genioglossus muscle, which is the largest upper airway dilator muscle. Activation of the genioglossus muscle causes tongue protrusion and, in some cases, anterior displacement of the soft palate, due to linkage via the palatoglossal arch (muscle). Anterior displacement of the soft palate, in turn, can cause tension to be applied to the lateral pharyngeal walls via the palatopharyngeal arch (muscle), the effect of which is discussed in more detail below. Thus, activation of the genioglossus muscle causes opening of the upper airway at the level of the tongue base (retro-glossal space) and, in some cases, at the level of the soft palate (retro-palatal space). Because the linkage between the genioglossus and the soft palate via the palatoglossal arch varies across subjects, the response to HGNS at the level of the palate will vary as well. This is significant because most people with OSA have some involvement of the palate during obstructive events, and it may be helpful to identify those subjects with inadequate retro-palatal opening due to poor linkage (i.e., poor coupling) between the genioglossus and soft palate, possibly due to tissue redundancy (i.e., slack) in the palatoglossus. Tissue redundancy may also be present in the lateral pharyngeal walls due to the presence of adipose tissue (i.e., fat) at discrete locations (e.g., fat pads) or distributed throughout the pharyngeal walls, particularly in patients with high BMI.


The anatomical linkage between the tongue base (genioglossus) and the soft palate via the palatoglossal arch may be more clearly seen in FIGS. 5 and 6. The palatoglossus muscle forms the palatoglossal arch and the anterior-inferior aspect of the soft palate on either side of the uvula. The inferior and lateral ends of the palatoglossus muscle insert into the genioglossus muscle. Posterior to the palatoglossal arch are the palatine tonsils, and posterior to the palatine tonsils is the palatopharyngeus muscle forming the palatopharyngeal arch and the posterior-inferior aspect of the soft palate on either side of the uvula. The inferior and lateral ends of the palatopharyngeus muscle insert into the lateral walls of the pharynx. The soft palate is also linked to the lateral pharyngeal walls inferiorly via the pharyngoepiglottic fold as best seen in FIG. 7. Activation of the genioglossus serves to pull the soft palate anteriorly via the palatoglossal linkage. Anterior displacement of the soft palate serves to apply anterior and lateral (outward) tension to the lateral pharyngeal walls via the palatopharyngeal linkage as well as the inferior lateral pharyngeal walls via the pharyngoepiglottic linkage.


The anatomical linkage between the tongue base (genioglossus) and the lateral pharyngeal walls may be better appreciated with reference to FIG. 8. The anterior-inferior aspect (not visible) of the styloglossus muscles insert into the genioglossus, and the posterior-superior aspect of the styloglossus muscles attach to the styloid process. Similarly, the anterior-inferior aspect (not visible) of the stylopharyngeus muscles insert into the lateral pharyngeal walls, and the posterior-superior aspect of the stylopharyngeus muscles attach to the styloid process. The glossopharyngeal aspects of the superior pharyngeal constrictor muscle also insert into the genioglossus. Thus, activation of the genioglossus serves to apply tension to the styloglossus and the glossopharyngeal aspects of the superior pharyngeal constrictor muscle, which in turn apply lateral outward tension to the lateral pharyngeal walls by virtue of the lateral outward position of the styloid process and the linkage via the stylopharyngeus muscles.


In sum, activation of the genioglossus muscle opens the retro-glossal airway as well as the retro-palatal airway via the linkages described above. In addition, activation of the genioglossus muscle serves to open the lateral pharyngeal walls via the linkages described above. However, the linked effects on the soft palate and the lateral pharyngeal walls is not present in all subjects but may be important for therapeutic success of HGNS depending on the level and mode of collapse in a given patient. By using a tongue protrusion maneuver to mimic the effect on the genioglossus muscle seen with HGNS, the response of the soft palate and lateral walls may be observed using endoscopy, for example. If the palatal and lateral walls respond sufficiently to the tongue protrusion maneuver, the likelihood of successful treatment with HGNS increases. Thus, observing the response of upper airway structures to the tongue protrusion maneuver may be used as a screening tool prior to implantation of a HGNS device.


Optionally, it may be desirable to observe the response of the airway at the level of collapse. The level of collapse may be determined during sleep or simulated sleep (e.g. sedation) using known techniques such as drug induced sleep endoscopy (DISE), or may be determined by examination of the airway structures using known techniques such as naso-endoscopy. The airway may collapse at the level of the tongue base (i.e., retro-glossal), at the level of the palate (i.e. retro-palatal), or both levels. Because most OSA patients have palatal involvement in airway collapse, it may not be necessary to determine the level of collapse. In this case, collapse may be assumed to occur at least at the level of the palate, and therefore an adequate response (e.g., increase in airway size) in the retro-palatal space during the tongue protrusion maneuver would be indicative of likely therapeutic success with HGNS.


The principles of the present invention may be applied to other therapeutic interventions for OSA involving the upper airway. For example, the tongue protrusion maneuver may be used as a screening tool for surgery of the upper airway, such as uvulopalatopharyngoplasty (UPPP), palatal implants, genioglossus advancement, maxillo-mandibular advancement, etc. Also, the tongue protrusion maneuver may be used as a screening tool for oral appliances such as mandibular repositioning devices, tongue retaining devices, etc.


Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departures in form and detail may be made without departing from the scope and spirit of the present invention as described in the appended claims.

Claims
  • 1. A method of assessing a patient's suitability for an upper airway stimulation therapy, the method comprising: inserting a visualization device into the patient's upper airway to evaluate a tissue linkage between the patient's genioglossus and at least one of the patient's soft palate and the patient's lateral pharyngeal walls;documenting a degree of tissue redundancy in said tissue linkage; andreceiving a criterion, the criterion concerning the patient's suitability for the upper airway stimulation therapy.
  • 2. The method of claim 1, wherein the tissue linkage communicates a movement of the patient's genioglossus to a corresponding movement of the patient's soft palate and/or lateral pharyngeal walls.
  • 3. The method of claim 1, wherein the degree of tissue redundancy corresponds to a quantity of adipose tissue observed in the patient's soft palate and/or lateral pharyngeal walls.
  • 4. The method of claim 1, further comprising: documenting the patient's body mass index (BMI).
  • 5. The method of claim 4, wherein the degree of tissue redundancy corresponds to a magnitude of the patient's BMI.
  • 6. The method of claim 1, further comprising: protruding the patient's tongue without nerve stimulation while observing a response of the patient's airway with the visualization device.
  • 7. The method of claim 1, wherein the documenting of the degree of tissue redundancy takes place when the patient is subjected to drug-induced sleep endoscopy (OISE).
  • 8. A method of assessing a patient's suitability for an upper airway stimulation therapy, the method comprising: inserting a visualization device into the patient's upper airway to evaluate a tissue linkage between the patient's genioglossus and at least one of the patient's soft palate and the patient's lateral pharyngeal walls;documenting a tissue redundancy presence in said tissue linkage; andreceiving a criterion, the criterion concerning the patient's suitability for the upper airway stimulation therapy.
  • 9. The method of claim 8, wherein the tissue linkage communicates a movement of the patient's genioglossus to a corresponding movement of the patient's soft palate and/or lateral pharyngeal walls.
  • 10. The method of claim 8, wherein the tissue redundancy presence corresponds to a quantity of adipose tissue observed in the patient's soft palate and/or lateral pharyngeal walls.
  • 11. The method of claim 8, further comprising: documenting the patient's body mass index (BMI).
  • 12. The method of claim 11, wherein the tissue redundancy presence corresponds to a magnitude of the patient's BMI.
  • 13. The method of claim 8, further comprising: protruding the patient's tongue without nerve stimulation while observing a response of the patient's airway with the visualization device.
  • 14. The method of claim 8, wherein the documenting of the tissue redundancy presence takes place when the patient is subjected to drug-induced sleep endoscopy (OISE).
  • 15. A method of assessing a patient's suitability for an upper airway stimulation therapy, the method comprising: recording with an imaging device at least a portion of a tissue linkage between the patient's genioglossus and at least one of the patient's soft palate and the patient's lateral pharyngeal walls;recording a tissue redundancy exhibited by said tissue linkage; andgenerating a record of said recordings, wherein the record includes a characterization of said tissue redundancy,wherein the record is configured for comparison to a criterion, the criterion concerning the patient's suitability for the upper airway stimulation therapy.
  • 16. The method of claim 15, wherein the tissue linkage communicates a movement of the patient's genioglossus to a corresponding movement of the patient's soft palate and/or lateral pharyngeal walls.
  • 17. The method of claim 15, wherein the characterization of said tissue redundancy corresponds to a quantity of adipose tissue observed in the patient's soft palate and/or lateral pharyngeal walls.
  • 18. The method of claim 15, further comprising: documenting the patient's body mass index (BMI).
  • 19. The method of claim 18, wherein the characterization of said tissue redundancy corresponds to a magnitude of the patient's BMI.
  • 20. The method of claim 15, further comprising: protruding the patient's tongue without nerve stimulation while observing a response of the patient's airway with the imaging device.
  • 21. The method of claim 15, wherein the record is generated when the patient is subjected to drug-induced sleep endoscopy (OISE).
CROSS REFERENCE TO RELATED APPLICATIONS

This patent application is a continuation of U.S. Patent Application No. 14/475,130, filed Sep. 2, 2014, entitled SCREENING DEVICES AND METHODS FOR OBSTRUCTIVE SLEEP APNEA THERAPY, now U.S. Patent No. 9,113,838, which is a continuation of U.S. Patent Application No. 13/205,315, filed Aug. 8, 2011, entitled SCREENING DEVICES AND METHODS FOR OBSTRUCTIVE SLEEP APNEA THERAPY, now U.S. Patent No. 8,855,771, which is a continuation of U.S. patent application Ser. No. 13/113,524, filed May 23, 2011, now abandoned, which claims the benefits of priority under 35 U.S.C. §§119 and 120 to U.S. Provisional Patent Application No. 61/437,573, filed Jan. 28, 2011, entitled OBSTRUCTIVE SLEEP APNEA TREATMENT DEVICES, SYSTEMS AND METHODS, and U.S. Provisional Patent Application No. 61/467,758, filed Mar. 25, 2011, entitled SCREENING DEVICES AND METHODS FOR OBSTRUCTIVE SLEEP APNEA THERAPY. This patent application is related to U.S. Patent Application No. 13/106,460, filed May 12, 2011, entitled OBSTRUCTIVE SLEEP APNEA TREATMENT DEVICES, SYSTEMS AND METHODS to Bolea et al., which claims the benefit of U.S. Provisional Patent Application No. 61/437,573, filed Jan. 28, 2011, entitled OBSTRUCTIVE SLEEP APNEA TREATMENT DEVICES, SYSTEMS AND METHODS. This patent application is also related to U.S. patent application Ser. No. 13/251,856, filed Oct. 3, 2011, now U.S. Patent No. 8,386,046, entitled SCREENING DEVICES AND METHODS FOR OBSTRUCTIVE SLEEP APNEA THERAPY, which is a continuation of U.S. patent application Ser. No. 13/205,315, filed Aug. 8, 2011, entitled SCREENING DEVICES AND METHODS FOR OBSTRUCTIVE SLEEP APNEA THERAPY, and to U.S. patent application Ser. No. 14/178,104, filed Feb. 11, 2014, entitled OBSTRUCTIVE SLEEP APNEA TREATMENT DEVICES, SYSTEMS AND METHODS, which is a continuation-in-part of U.S. patent application Ser. No. 13/205,315. The entire disclosures of all of the above-listed applications are incorporated herein by reference.

US Referenced Citations (372)
Number Name Date Kind
758030 Carence Apr 1904 A
1520930 Calhoun Dec 1924 A
1701277 Shindel Feb 1929 A
1914418 Goyena Jun 1933 A
2046664 Weaver Jul 1936 A
2151227 Pawelek Mar 1939 A
2237954 Wilson Apr 1941 A
2243360 Slatis May 1941 A
2274886 Carroll Mar 1942 A
2526586 Shuff Oct 1950 A
2693799 Herman Nov 1954 A
2777442 Zelano Jan 1957 A
2928388 Jaroslaw Mar 1960 A
3457917 Mercurio Jul 1969 A
3513839 Vacante May 1970 A
3680555 Warncke Aug 1972 A
3722509 Nebel Mar 1973 A
3774618 Avery Nov 1973 A
3865106 Palush Feb 1975 A
3884223 Keindl May 1975 A
3906936 Habal Sep 1975 A
4220150 King Sep 1980 A
4221217 Amezcua Sep 1980 A
4267831 Aguilar May 1981 A
4374527 Iversen Feb 1983 A
4567892 Plicchi et al. Feb 1986 A
4573481 Bullara Mar 1986 A
4777963 McKenna Oct 1988 A
4830008 Meer May 1989 A
4899750 Eckwall Feb 1990 A
4915105 Lee Apr 1990 A
4919136 Alt Apr 1990 A
4940065 Tanagho et al. Jul 1990 A
4960133 Hewson Oct 1990 A
4996983 AmRhein Mar 1991 A
5016808 Heil, Jr. et al. May 1991 A
5105826 Smits et al. Apr 1992 A
5121754 Mullett Jun 1992 A
5133354 Kallock Jul 1992 A
5146918 Kallok et al. Sep 1992 A
5158080 Kallock Oct 1992 A
5174287 Kallok et al. Dec 1992 A
5178156 Takishima et al. Jan 1993 A
5190053 Meer Mar 1993 A
5211173 Kallok et al. May 1993 A
5215082 Kallok et al. Jun 1993 A
5277193 Takishima et al. Jan 1994 A
5281219 Kallok et al. Jan 1994 A
5300094 Kallok et al. Apr 1994 A
5324321 Pohndorf et al. Jun 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5344438 Testerman et al. Sep 1994 A
5388578 Yomtov et al. Feb 1995 A
5392773 Bertrand Feb 1995 A
5417205 Wang May 1995 A
5425359 Liou Jun 1995 A
5458629 Baudino et al. Oct 1995 A
5483969 Testerman et al. Jan 1996 A
5485836 Lincoln Jan 1996 A
5485851 Erickson Jan 1996 A
5511543 Shirley Apr 1996 A
5522382 Sullivan et al. Jun 1996 A
5522862 Testerman et al. Jun 1996 A
5531778 Maschino et al. Jul 1996 A
5540732 Testerman Jul 1996 A
5540733 Testerman et al. Jul 1996 A
5540734 Zabara Jul 1996 A
5546938 McKenzie Aug 1996 A
5549655 Erickson Aug 1996 A
5568808 Rimkus Oct 1996 A
5591216 Testerman et al. Jan 1997 A
5630411 Holscher May 1997 A
5682881 Winthrop et al. Nov 1997 A
5697105 White Dec 1997 A
5697363 Hart Dec 1997 A
5730122 Lurie Mar 1998 A
5740798 McKinney Apr 1998 A
5752511 Simmons et al. May 1998 A
5787884 Tovey Aug 1998 A
5826579 Remmers et al. Oct 1998 A
5848589 Welnetz Dec 1998 A
5855552 Houser et al. Jan 1999 A
5890491 Rimkus Apr 1999 A
5895360 Christopherson et al. Apr 1999 A
5922014 Warman et al. Jul 1999 A
5938596 Woloszko et al. Aug 1999 A
5944680 Christopherson et al. Aug 1999 A
5947119 Reznick Sep 1999 A
6010459 Silkoff et al. Jan 2000 A
6015389 Brown Jan 2000 A
6021352 Christopherson et al. Feb 2000 A
6021354 Warman et al. Feb 2000 A
6029667 Lurie Feb 2000 A
6041780 Richard Mar 2000 A
6066165 Racz May 2000 A
6098624 Utamaru Aug 2000 A
6109262 Tovey Aug 2000 A
6119690 Pantaleo Sep 2000 A
6126611 Bourgeois et al. Oct 2000 A
6132384 Christopherson et al. Oct 2000 A
6198970 Freed et al. Mar 2001 B1
6201994 Warman et al. Mar 2001 B1
6205360 Carter et al. Mar 2001 B1
6217527 Selmon et al. Apr 2001 B1
6221049 Selmon et al. Apr 2001 B1
6231546 Milo et al. May 2001 B1
6240316 Richmond et al. May 2001 B1
6244267 Eifrig Jun 2001 B1
6251126 Ottenhoff et al. Jun 2001 B1
6269269 Ottenhoff et al. Jul 2001 B1
6345202 Richmond et al. Feb 2002 B2
6366815 Haugland et al. Apr 2002 B1
6460539 Japuntich et al. Oct 2002 B1
6484725 Chi Nov 2002 B1
6511458 Milo et al. Jan 2003 B2
6514217 Selmon et al. Feb 2003 B1
6542776 Gordon et al. Apr 2003 B1
6561188 Ellis May 2003 B1
6587725 Durand et al. Jul 2003 B1
6600956 Maschino et al. Jul 2003 B2
6606521 Paspa et al. Aug 2003 B2
6626179 Pedley Sep 2003 B1
6636767 Knudson et al. Oct 2003 B1
6641542 Cho et al. Nov 2003 B2
6647289 Prutchi Nov 2003 B2
6651652 Ward Nov 2003 B1
6718982 Smith et al. Apr 2004 B2
6719725 Milo et al. Apr 2004 B2
6721603 Zabara et al. Apr 2004 B2
6772015 Dahl et al. Aug 2004 B2
6776162 Wood Aug 2004 B2
6799575 Carter Oct 2004 B1
6819958 Weiner et al. Nov 2004 B2
6829503 Alt Dec 2004 B2
6829508 Schulman et al. Dec 2004 B2
RE38705 Hill et al. Feb 2005 E
6876885 Swoyer et al. Apr 2005 B2
6881192 Park Apr 2005 B1
6883518 Mittelstadt et al. Apr 2005 B2
6890306 Poezevera May 2005 B2
6904320 Park et al. Jun 2005 B2
6907295 Gross et al. Jun 2005 B2
6928324 Park et al. Aug 2005 B2
6978171 Goetz et al. Dec 2005 B2
6997177 Wood Feb 2006 B2
7027869 Danek et al. Apr 2006 B2
7054692 Whitehurst et al. May 2006 B1
7065410 Bardy et al. Jun 2006 B2
7082331 Park et al. Jul 2006 B1
7087053 Vanney Aug 2006 B2
7089932 Dodds Aug 2006 B2
7094206 Hoffman Aug 2006 B2
7117036 Florio Oct 2006 B2
7128717 Thatch et al. Oct 2006 B1
7142919 Hine et al. Nov 2006 B2
7149573 Wang Dec 2006 B2
7152604 Hickle et al. Dec 2006 B2
7155278 King et al. Dec 2006 B2
7156098 Dolezal et al. Jan 2007 B2
7160252 Cho Jan 2007 B2
7160255 Saadat Jan 2007 B2
7178524 Noble Feb 2007 B2
7200440 Kim et al. Apr 2007 B2
7225034 Ries et al. May 2007 B2
7239918 Strother et al. Jul 2007 B2
7239920 Thacker et al. Jul 2007 B1
7242987 Holleman et al. Jul 2007 B2
7277749 Gordon et al. Oct 2007 B2
7283867 Strother et al. Oct 2007 B2
7302951 Mittelstadt et al. Dec 2007 B2
7313442 Velasco et al. Dec 2007 B2
7346398 Gross et al. Mar 2008 B2
7366572 Heruth et al. Apr 2008 B2
7396333 Stahmann et al. Jul 2008 B2
7438686 Cho et al. Oct 2008 B2
7463928 Lee et al. Dec 2008 B2
7473227 Hsu et al. Jan 2009 B2
7515968 Metzler et al. Apr 2009 B2
7524292 Cho et al. Apr 2009 B2
7561922 Cohen et al. Jul 2009 B2
7591265 Lee et al. Sep 2009 B2
7596413 Libbus et al. Sep 2009 B2
7596414 Whitehurst et al. Sep 2009 B2
7627375 Bardy et al. Dec 2009 B2
7630771 Cauller Dec 2009 B2
7634315 Cholette Dec 2009 B2
7636602 Baru Fassio et al. Dec 2009 B2
7657311 Bardy et al. Feb 2010 B2
7660632 Kirby et al. Feb 2010 B2
7662105 Hatlestad Feb 2010 B2
7672728 Libbus et al. Mar 2010 B2
7672729 Koh et al. Mar 2010 B2
7680537 Stahmann et al. Mar 2010 B2
7680538 Durand et al. Mar 2010 B2
7684869 Bradley et al. Mar 2010 B2
7697968 Moore Apr 2010 B2
7697984 Hill et al. Apr 2010 B2
7697990 Ujhazy et al. Apr 2010 B2
7717848 Heruth et al. May 2010 B2
7720534 Bardy et al. May 2010 B2
7725195 Lima et al. May 2010 B2
7725198 Cross, Jr. et al. May 2010 B2
7734340 De Ridder Jun 2010 B2
7734348 Zhang et al. Jun 2010 B2
7738952 Yun et al. Jun 2010 B2
7747323 Libbus et al. Jun 2010 B2
7751880 Cholette Jul 2010 B1
7751885 Bardy et al. Jul 2010 B2
7758384 Alexander et al. Jul 2010 B2
7765000 Zhang et al. Jul 2010 B2
7769461 Whitehurst et al. Aug 2010 B2
7783353 Libbus et al. Aug 2010 B2
7785262 Melker et al. Aug 2010 B2
7787959 Morgan Aug 2010 B1
7792590 Pianca et al. Sep 2010 B1
7797050 Libbus et al. Sep 2010 B2
7797057 Harris Sep 2010 B2
7797058 Mrva et al. Sep 2010 B2
7805195 Zealear Sep 2010 B2
7809442 Bolea et al. Oct 2010 B2
7813797 Bardy et al. Oct 2010 B2
7813802 Tcheng et al. Oct 2010 B2
7813809 Strother et al. Oct 2010 B2
7818063 Wallace et al. Oct 2010 B2
7822486 Foster et al. Oct 2010 B2
8249723 McCreery Aug 2012 B2
8386046 Tesfayesus et al. Feb 2013 B2
20010010010 Richmond et al. Jul 2001 A1
20010031929 O'Toole Oct 2001 A1
20020010495 Freed et al. Jan 2002 A1
20020049479 Pitts Apr 2002 A1
20020092527 Wood Jul 2002 A1
20020128700 Cross Sep 2002 A1
20020166556 Jacob Nov 2002 A1
20020195108 Mittelstadt et al. Dec 2002 A1
20020195109 Mittelstadt et al. Dec 2002 A1
20030034031 Lev et al. Feb 2003 A1
20030083696 Avital May 2003 A1
20030093128 Freed et al. May 2003 A1
20030106555 Tovey Jun 2003 A1
20030106556 Alperovich et al. Jun 2003 A1
20030114895 Gordon et al. Jun 2003 A1
20030114905 Kuzma Jun 2003 A1
20030167018 Wyckoff Sep 2003 A1
20030195571 Burnes et al. Oct 2003 A1
20030209145 Soper Nov 2003 A1
20030216789 Deem et al. Nov 2003 A1
20040015204 Whitehurst et al. Jan 2004 A1
20040020489 Gillespie et al. Feb 2004 A1
20040049241 Campos Mar 2004 A1
20040055603 Bruce Mar 2004 A1
20040073272 Knudson et al. Apr 2004 A1
20040089303 Chien May 2004 A1
20040111139 McCreery Jun 2004 A1
20040116819 Alt Jun 2004 A1
20040116978 Bradley Jun 2004 A1
20040162499 Nagai et al. Aug 2004 A1
20040194784 Bertrand Oct 2004 A1
20040215288 Lee et al. Oct 2004 A1
20040230278 Dahl et al. Nov 2004 A1
20040233058 Dodds Nov 2004 A1
20040260310 Harris Dec 2004 A1
20040261791 Horian Dec 2004 A1
20050004610 Kim et al. Jan 2005 A1
20050010265 Fassio et al. Jan 2005 A1
20050038490 Gross et al. Feb 2005 A1
20050039757 Wood Feb 2005 A1
20050043644 Stahmann et al. Feb 2005 A1
20050043772 Stahmann et al. Feb 2005 A1
20050076908 Lee et al. Apr 2005 A1
20050085865 Tehrani Apr 2005 A1
20050085866 Tehrani Apr 2005 A1
20050085868 Tehrani et al. Apr 2005 A1
20050085869 Tehrani et al. Apr 2005 A1
20050085874 Davis et al. Apr 2005 A1
20050098176 Hoffrichter May 2005 A1
20050101833 Hsu et al. May 2005 A1
20050119711 Cho et al. Jun 2005 A1
20050139216 Mittelstadt et al. Jun 2005 A1
20050165457 Benser et al. Jul 2005 A1
20050209513 Heruth et al. Sep 2005 A1
20050209643 Heruth et al. Sep 2005 A1
20050234523 Levin et al. Oct 2005 A1
20050235992 Djupesland Oct 2005 A1
20050240241 Yun et al. Oct 2005 A1
20050251216 Hill et al. Nov 2005 A1
20050261747 Schuler et al. Nov 2005 A1
20050267380 Poezevara Dec 2005 A1
20050267547 Knudson et al. Dec 2005 A1
20050277844 Strother et al. Dec 2005 A1
20050277999 Strother et al. Dec 2005 A1
20050278000 Strother et al. Dec 2005 A1
20060005842 Rashad et al. Jan 2006 A1
20060025828 Armstrong et al. Feb 2006 A1
20060030919 Mrva et al. Feb 2006 A1
20060032497 Doshi Feb 2006 A1
20060052836 Kim et al. Mar 2006 A1
20060058588 Zdeblick Mar 2006 A1
20060058852 Koh et al. Mar 2006 A1
20060064029 Arad Mar 2006 A1
20060064138 Velasco et al. Mar 2006 A1
20060079802 Jensen et al. Apr 2006 A1
20060095088 De Ridder May 2006 A1
20060111755 Stone et al. May 2006 A1
20060116739 Betser et al. Jun 2006 A1
20060129189 George et al. Jun 2006 A1
20060135886 Lippert et al. Jun 2006 A1
20060136024 Cohen et al. Jun 2006 A1
20060142815 Tehrani et al. Jun 2006 A1
20060144398 Doshi et al. Jul 2006 A1
20060150978 Doshi et al. Jul 2006 A1
20060150979 Doshi et al. Jul 2006 A1
20060150980 Kim Jul 2006 A1
20060167497 Armstrong et al. Jul 2006 A1
20060184204 He Aug 2006 A1
20060195170 Cohen et al. Aug 2006 A1
20060211951 Milajasevic et al. Sep 2006 A1
20060224209 Meyer Oct 2006 A1
20060224211 Durand Oct 2006 A1
20060241506 Melker et al. Oct 2006 A1
20060241708 Boute Oct 2006 A1
20060247729 Tehrani et al. Nov 2006 A1
20060259079 King Nov 2006 A1
20060264777 Drew Nov 2006 A1
20060266369 Atkinson et al. Nov 2006 A1
20060271118 Libbus et al. Nov 2006 A1
20060271137 Stanton-Hicks Nov 2006 A1
20060282127 Zealear Dec 2006 A1
20060293720 DiLorenzo Dec 2006 A1
20060293723 Whitehurst et al. Dec 2006 A1
20070021785 Inman et al. Jan 2007 A1
20070027482 Parnis et al. Feb 2007 A1
20070038265 Tcheng et al. Feb 2007 A1
20070043411 Foster et al. Feb 2007 A1
20070095347 Lampotang et al. May 2007 A1
20070125379 Pierro et al. Jun 2007 A1
20070175478 Brunst Aug 2007 A1
20070227542 Kashmakov et al. Oct 2007 A1
20070277832 Doshi et al. Dec 2007 A1
20070283692 Tetsuka et al. Dec 2007 A1
20070283962 Doshi et al. Dec 2007 A1
20070295338 Loomas et al. Dec 2007 A1
20080023007 Dolezal et al. Jan 2008 A1
20080027480 van der Burg et al. Jan 2008 A1
20080041373 Doshi et al. Feb 2008 A1
20080103545 Bolea et al. May 2008 A1
20080163875 Aarestad et al. Jul 2008 A1
20080183254 Bly et al. Jul 2008 A1
20090270707 Alfoqaha et al. Oct 2009 A1
20090276024 Bonde et al. Nov 2009 A1
20090308395 Lee et al. Dec 2009 A1
20090318986 Alo et al. Dec 2009 A1
20090326408 Moon et al. Dec 2009 A1
20100016749 Atsma et al. Jan 2010 A1
20100036285 Govari et al. Feb 2010 A1
20100047376 Imbeau et al. Feb 2010 A1
20100076536 Merz et al. Mar 2010 A1
20100094379 Meadows et al. Apr 2010 A1
20100100150 Kirby et al. Apr 2010 A1
20100125310 Wilson et al. May 2010 A1
20100131029 Durand et al. May 2010 A1
20100137931 Hopper et al. Jun 2010 A1
20100137949 Mazgalev et al. Jun 2010 A1
20100137956 Osypka et al. Jun 2010 A1
20100152553 Ujhazy et al. Jun 2010 A1
20100174341 Bolea et al. Jul 2010 A1
20100228133 Averina et al. Sep 2010 A1
20100228317 Libbus et al. Sep 2010 A1
20100241207 Bluger Sep 2010 A1
20100257729 Alexander et al. Oct 2010 A1
20100262209 King et al. Oct 2010 A1
20110093032 Boggs, II Apr 2011 A1
Foreign Referenced Citations (22)
Number Date Country
0 892 926 Jun 2002 EP
0 900 102 Jul 2004 EP
1 854 494 Nov 2007 EP
53118893 Oct 1978 JP
9-294819 Nov 1997 JP
2000-506601 May 2000 JP
2000-508562 Jul 2000 JP
2003-305135 Oct 2003 JP
2004-508908 Mar 2004 JP
2004-532707 Oct 2004 JP
3688301 Jun 2005 JP
2005-521485 Jul 2005 JP
2007-21156 Feb 2007 JP
WO 9820938 May 1998 WO
WO 0224279 Mar 2002 WO
WO 03000133 Jan 2003 WO
WO 03000347 Jan 2003 WO
WO 03082393 Oct 2003 WO
WO 2005004993 Jan 2005 WO
WO 2006045251 May 2006 WO
WO 2006063339 Jun 2006 WO
WO 2007134458 Nov 2007 WO
Non-Patent Literature Citations (18)
Entry
Kirkness et al., “Nasal airflow dynamics: mechanisms and responses associated with an external nasal dilator strip,” University of Western Sydney, T.C. Amis School of Science, Department of Respiratory Medicine, Westmead Hospital and University of Sydney, Westmead, Australia, 2000.
De Almeida et al., “Nasal pressure recordings to detect obstructive sleep apnea,” Sleep and Breathing, Feb. 25, 2006, pp. 62-69, vol. 10 (2), Springer Heidelberg.
Saslow et al., “Work of breathing using high-flow nasal cannula in preterm infants,” Journal of Perinatology, May 11, 2006, pp. 476-480, vol. 26 (8), Nature Publishing Group.
Campbell et al., “Nasal Continuous positive airway pressure from high flow cannula versus Infant Flow for preterm infants,” Journal of Perinatology, Jul. 2006, pp. 546-549, vol. 26 (9), Nature Publishing Group.
Trevisanuto et al., “A new device for administration of continuous positive airway pressure in preterm infants: comparison with a standard nasal CPAP continuous positive airway pressure system,” Intensive Care Medicine, Apr. 2005, pp. 859-864, vol. 31 (6), Springer-Verlag.
Verse et al., “New developments in the therapy of obstructive sleep apnea,” European Archives of Oto-Rhino-Laryngology, Jan. 2001, pp. 31-37, vol. 258 (1), Springer-Verlag.
Paquereau et al., “Positive pressure titration in the treatment of obstructive sleep apnea syndrome using continuous airway positive pressure,” Revue Des Maladies Respiratoires, Apr. 2000, pp. 459-465, vol. 17 (2), Masson Editeur.
Mahadevia et al., “Effects of expiratory positive airway pressure on sleep-induced respiratory abnormalities in patients with hypersomnia-sleep apnea syndrome,” Am. Rev. Respir. Dis., Feb. 1983, vol. 128, pp. 708-711.
Tiran et al., “An Improved Device for Posterior Rhinomanometry to Measure Nasal Resistance,” Journal of Biomechnical Engineering, Nov. 2005, vol. 127, pp. 994-997.
Noseda et al., “Compliance with nasal continuous positive airway pressure assessed with a pressure monitor: pattern of use and influence of sleep habits,” Chest Clinics and Sleep Laboratories, Hôpitaux Erasme et Brugmann, Université Libre de Bruxelles, Brussels, Belgium, 2000, vol. 94, pp. 76-81.
Goding Jr. et al., “Relief of Upper Airway Obstruction With Hypoglossal Nerve Stimulation in the Canine,” The Laryngoscope, Feb. 1998, pp. 162-169, vol. 108, Lippincott-Raven Publishers, U.S.A.
Sahin et al., “Chronic recordings of hypoglossal nerve activity in a dog model of upper airway obstruction,” Journal of Applied Physiology 87(6), 1999, The American Physiological Society, pp. 2197-2206.
Ferguson et al., “Effect of Mandibular and Tongue Protrusion on Upper Airway Size During Wakefulness,” American Journal of Respiratory and Critical Care Medicine, 1997, pp. 1748-1754, vol. 155.
Isono et al., “Interaction of cross-sectional area, driving pressure, and airflow of passive velopharynx,” American Physiological Society, 1997, pp. 851-859, vol. 83.
Oliven et al., “Effect of genioglossus contraction on pharyngeal lumen and airflow in sleep apnoea patients,” European Respiratory Journal, 2007, pp. 748-758, vol. 30, No. 4.
Eastwood et al., “Treating Obstructive Sleep Apnea with Hypoglossal Nerve Stimulation,” Sleep, 2011, pp. 1479-1486B, vol. 34, No. 11.
Strollo et al., “Upper-Airway Stimulation for Obstructive Sleep Apnea,” New England Journal of Medicine, 2014, pp. 139-149, N Engl J. Med 270;2.
European Search Report for Patent Application No. 16162666, dated Jul. 8, 2016, 7 pages.
Related Publications (1)
Number Date Country
20150321008 A1 Nov 2015 US
Provisional Applications (2)
Number Date Country
61467758 Mar 2011 US
61437573 Jan 2011 US
Continuations (3)
Number Date Country
Parent 14475130 Sep 2014 US
Child 14803779 US
Parent 13205315 Aug 2011 US
Child 14475130 US
Parent 13113524 May 2011 US
Child 13205315 US